Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
Background Angiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC). However, few clinical data are available regarding the efficacy of cabozantinib following immunotherapy. Objective To describe the ou...
Gespeichert in:
| Veröffentlicht in: | Targeted oncology 2020-08, Vol.15 (4), p.495-501 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 501 |
|---|---|
| container_issue | 4 |
| container_start_page | 495 |
| container_title | Targeted oncology |
| container_volume | 15 |
| creator | Iacovelli, Roberto Ciccarese, Chiara Facchini, Gaetano Milella, Michele Urbano, Federica Basso, Umberto De Giorgi, Ugo Sabbatini, Roberto Santini, Daniele Berardi, Rossana Santoni, Matteo Bracarda, Sergio Massari, Francesco Masini, Cristina De Tursi, Michele Ricotta, Riccardo Buti, Sebastiano Zustovich, Fable Sepe, Pierangela Rossetti, Sabrina Maruzzo, Marco Cortesi, Enrico Tortora, Giampaolo Procopio, Giuseppe |
| description | Background
Angiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC). However, few clinical data are available regarding the efficacy of cabozantinib following immunotherapy.
Objective
To describe the outcome of cabozantinib in patients previously treated with immunotherapy.
Patients and methods
Patients with mRCC who received cabozantinib immediately after nivolumab were included. The primary endpoint was to assess the outcome in terms of efficacy and activity.
Results
Eighty-four mRCC patients met the criteria to be included in the final analysis. After a median follow-up of 9.4 months, median overall survival was 17.3 months. According to the IMDC criteria, the rates of patients alive at 12 months in the good, intermediate, and poor prognostic groups were 100%, 74%, and 33%, respectively (
p
|
| doi_str_mv | 10.1007/s11523-020-00732-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2424446591</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2424446591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-3c6b09895ca64d3f91062d5c61aad57f619a7d3ece78e0357101f2daac6f7fa23</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSNERUvhBVggS2zYhPonthN2o6jASK1ACCR21o1zQ10m9mA7laaPwFPjYdoisWBz_fed43t1quoFo28YpfosMSa5qCmndTkKXu8eVSdMa1VzRb89vt_LTh1XT1O6prTRXNIn1bHgSrOW6pPqVw9DuAWfnXcDWU0ZIwHyKeKNC0si63lePJL-Cu2PbXA-k7W_coPLIRLnySVmSBmys-QzetiQHjelQLTOhxneklW5zzGkLdrsbpBcLpvs6rVP2eUlu7DXrErZJZeeVUcTbBI-v1tPq6_vzr_0H-qLj-_X_eqitk0rcy2sGmjXdtKCakYxdYwqPkqrGMAo9aRYB3oUaFG3SIXUjLKJjwBWTXoCLk6r1wffbQw_F0zZzC7Z0jh4LDMb3vCmaZTsWEFf_YNehyWWfveUkJS3olGF4gfKlklTxMlso5sh7gyjZp-UOSRlSlLmT1JmV0Qv76yXYcbxQXIfTQHEAUjlyX_H-Pfv_9j-BtAkoNk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435028346</pqid></control><display><type>article</type><title>Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis</title><source>SpringerLink Journals</source><creator>Iacovelli, Roberto ; Ciccarese, Chiara ; Facchini, Gaetano ; Milella, Michele ; Urbano, Federica ; Basso, Umberto ; De Giorgi, Ugo ; Sabbatini, Roberto ; Santini, Daniele ; Berardi, Rossana ; Santoni, Matteo ; Bracarda, Sergio ; Massari, Francesco ; Masini, Cristina ; De Tursi, Michele ; Ricotta, Riccardo ; Buti, Sebastiano ; Zustovich, Fable ; Sepe, Pierangela ; Rossetti, Sabrina ; Maruzzo, Marco ; Cortesi, Enrico ; Tortora, Giampaolo ; Procopio, Giuseppe</creator><creatorcontrib>Iacovelli, Roberto ; Ciccarese, Chiara ; Facchini, Gaetano ; Milella, Michele ; Urbano, Federica ; Basso, Umberto ; De Giorgi, Ugo ; Sabbatini, Roberto ; Santini, Daniele ; Berardi, Rossana ; Santoni, Matteo ; Bracarda, Sergio ; Massari, Francesco ; Masini, Cristina ; De Tursi, Michele ; Ricotta, Riccardo ; Buti, Sebastiano ; Zustovich, Fable ; Sepe, Pierangela ; Rossetti, Sabrina ; Maruzzo, Marco ; Cortesi, Enrico ; Tortora, Giampaolo ; Procopio, Giuseppe</creatorcontrib><description>Background
Angiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC). However, few clinical data are available regarding the efficacy of cabozantinib following immunotherapy.
Objective
To describe the outcome of cabozantinib in patients previously treated with immunotherapy.
Patients and methods
Patients with mRCC who received cabozantinib immediately after nivolumab were included. The primary endpoint was to assess the outcome in terms of efficacy and activity.
Results
Eighty-four mRCC patients met the criteria to be included in the final analysis. After a median follow-up of 9.4 months, median overall survival was 17.3 months. According to the IMDC criteria, the rates of patients alive at 12 months in the good, intermediate, and poor prognostic groups were 100%, 74%, and 33%, respectively (
p
< 0.001). The median progression-free survival (PFS) was 11.5 months (95% CI 8.3–14.7); no difference was found based on duration of previous first-line therapy or nivolumab PFS. The overall response rate was 52%, stable disease was found as the best response in 25.3% and progressive disease in 22.7% of patients. Among the 35 patients with progressive disease on nivolumab, 26 (74.3%) patients showed complete/partial response or stable disease with cabozantinib as best response after nivolumab. The major limitations of this study are the retrospective nature and the short follow-up.
Conclusions
Cabozantinib was shown to be effective and active in patients previously receiving immune checkpoint inhibitors. Therefore, cabozantinib can be considered a valid therapeutic option for previously treated mRCC patients, irrespective of the type and duration of prior therapies.</description><identifier>ISSN: 1776-2596</identifier><identifier>EISSN: 1776-260X</identifier><identifier>DOI: 10.1007/s11523-020-00732-y</identifier><identifier>PMID: 32671807</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biomedicine ; Immunotherapy ; Inhibitor drugs ; Kidney cancer ; Medicine ; Medicine & Public Health ; Metastasis ; Monoclonal antibodies ; Oncology ; Original Research Article ; Targeted cancer therapy</subject><ispartof>Targeted oncology, 2020-08, Vol.15 (4), p.495-501</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>Springer Nature Switzerland AG 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-3c6b09895ca64d3f91062d5c61aad57f619a7d3ece78e0357101f2daac6f7fa23</citedby><cites>FETCH-LOGICAL-c485t-3c6b09895ca64d3f91062d5c61aad57f619a7d3ece78e0357101f2daac6f7fa23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11523-020-00732-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11523-020-00732-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32671807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iacovelli, Roberto</creatorcontrib><creatorcontrib>Ciccarese, Chiara</creatorcontrib><creatorcontrib>Facchini, Gaetano</creatorcontrib><creatorcontrib>Milella, Michele</creatorcontrib><creatorcontrib>Urbano, Federica</creatorcontrib><creatorcontrib>Basso, Umberto</creatorcontrib><creatorcontrib>De Giorgi, Ugo</creatorcontrib><creatorcontrib>Sabbatini, Roberto</creatorcontrib><creatorcontrib>Santini, Daniele</creatorcontrib><creatorcontrib>Berardi, Rossana</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Bracarda, Sergio</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><creatorcontrib>Masini, Cristina</creatorcontrib><creatorcontrib>De Tursi, Michele</creatorcontrib><creatorcontrib>Ricotta, Riccardo</creatorcontrib><creatorcontrib>Buti, Sebastiano</creatorcontrib><creatorcontrib>Zustovich, Fable</creatorcontrib><creatorcontrib>Sepe, Pierangela</creatorcontrib><creatorcontrib>Rossetti, Sabrina</creatorcontrib><creatorcontrib>Maruzzo, Marco</creatorcontrib><creatorcontrib>Cortesi, Enrico</creatorcontrib><creatorcontrib>Tortora, Giampaolo</creatorcontrib><creatorcontrib>Procopio, Giuseppe</creatorcontrib><title>Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis</title><title>Targeted oncology</title><addtitle>Targ Oncol</addtitle><addtitle>Target Oncol</addtitle><description>Background
Angiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC). However, few clinical data are available regarding the efficacy of cabozantinib following immunotherapy.
Objective
To describe the outcome of cabozantinib in patients previously treated with immunotherapy.
Patients and methods
Patients with mRCC who received cabozantinib immediately after nivolumab were included. The primary endpoint was to assess the outcome in terms of efficacy and activity.
Results
Eighty-four mRCC patients met the criteria to be included in the final analysis. After a median follow-up of 9.4 months, median overall survival was 17.3 months. According to the IMDC criteria, the rates of patients alive at 12 months in the good, intermediate, and poor prognostic groups were 100%, 74%, and 33%, respectively (
p
< 0.001). The median progression-free survival (PFS) was 11.5 months (95% CI 8.3–14.7); no difference was found based on duration of previous first-line therapy or nivolumab PFS. The overall response rate was 52%, stable disease was found as the best response in 25.3% and progressive disease in 22.7% of patients. Among the 35 patients with progressive disease on nivolumab, 26 (74.3%) patients showed complete/partial response or stable disease with cabozantinib as best response after nivolumab. The major limitations of this study are the retrospective nature and the short follow-up.
Conclusions
Cabozantinib was shown to be effective and active in patients previously receiving immune checkpoint inhibitors. Therefore, cabozantinib can be considered a valid therapeutic option for previously treated mRCC patients, irrespective of the type and duration of prior therapies.</description><subject>Biomedicine</subject><subject>Immunotherapy</subject><subject>Inhibitor drugs</subject><subject>Kidney cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Original Research Article</subject><subject>Targeted cancer therapy</subject><issn>1776-2596</issn><issn>1776-260X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kc1u1DAUhSNERUvhBVggS2zYhPonthN2o6jASK1ACCR21o1zQ10m9mA7laaPwFPjYdoisWBz_fed43t1quoFo28YpfosMSa5qCmndTkKXu8eVSdMa1VzRb89vt_LTh1XT1O6prTRXNIn1bHgSrOW6pPqVw9DuAWfnXcDWU0ZIwHyKeKNC0si63lePJL-Cu2PbXA-k7W_coPLIRLnySVmSBmys-QzetiQHjelQLTOhxneklW5zzGkLdrsbpBcLpvs6rVP2eUlu7DXrErZJZeeVUcTbBI-v1tPq6_vzr_0H-qLj-_X_eqitk0rcy2sGmjXdtKCakYxdYwqPkqrGMAo9aRYB3oUaFG3SIXUjLKJjwBWTXoCLk6r1wffbQw_F0zZzC7Z0jh4LDMb3vCmaZTsWEFf_YNehyWWfveUkJS3olGF4gfKlklTxMlso5sh7gyjZp-UOSRlSlLmT1JmV0Qv76yXYcbxQXIfTQHEAUjlyX_H-Pfv_9j-BtAkoNk</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Iacovelli, Roberto</creator><creator>Ciccarese, Chiara</creator><creator>Facchini, Gaetano</creator><creator>Milella, Michele</creator><creator>Urbano, Federica</creator><creator>Basso, Umberto</creator><creator>De Giorgi, Ugo</creator><creator>Sabbatini, Roberto</creator><creator>Santini, Daniele</creator><creator>Berardi, Rossana</creator><creator>Santoni, Matteo</creator><creator>Bracarda, Sergio</creator><creator>Massari, Francesco</creator><creator>Masini, Cristina</creator><creator>De Tursi, Michele</creator><creator>Ricotta, Riccardo</creator><creator>Buti, Sebastiano</creator><creator>Zustovich, Fable</creator><creator>Sepe, Pierangela</creator><creator>Rossetti, Sabrina</creator><creator>Maruzzo, Marco</creator><creator>Cortesi, Enrico</creator><creator>Tortora, Giampaolo</creator><creator>Procopio, Giuseppe</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200801</creationdate><title>Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis</title><author>Iacovelli, Roberto ; Ciccarese, Chiara ; Facchini, Gaetano ; Milella, Michele ; Urbano, Federica ; Basso, Umberto ; De Giorgi, Ugo ; Sabbatini, Roberto ; Santini, Daniele ; Berardi, Rossana ; Santoni, Matteo ; Bracarda, Sergio ; Massari, Francesco ; Masini, Cristina ; De Tursi, Michele ; Ricotta, Riccardo ; Buti, Sebastiano ; Zustovich, Fable ; Sepe, Pierangela ; Rossetti, Sabrina ; Maruzzo, Marco ; Cortesi, Enrico ; Tortora, Giampaolo ; Procopio, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-3c6b09895ca64d3f91062d5c61aad57f619a7d3ece78e0357101f2daac6f7fa23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomedicine</topic><topic>Immunotherapy</topic><topic>Inhibitor drugs</topic><topic>Kidney cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Original Research Article</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iacovelli, Roberto</creatorcontrib><creatorcontrib>Ciccarese, Chiara</creatorcontrib><creatorcontrib>Facchini, Gaetano</creatorcontrib><creatorcontrib>Milella, Michele</creatorcontrib><creatorcontrib>Urbano, Federica</creatorcontrib><creatorcontrib>Basso, Umberto</creatorcontrib><creatorcontrib>De Giorgi, Ugo</creatorcontrib><creatorcontrib>Sabbatini, Roberto</creatorcontrib><creatorcontrib>Santini, Daniele</creatorcontrib><creatorcontrib>Berardi, Rossana</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Bracarda, Sergio</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><creatorcontrib>Masini, Cristina</creatorcontrib><creatorcontrib>De Tursi, Michele</creatorcontrib><creatorcontrib>Ricotta, Riccardo</creatorcontrib><creatorcontrib>Buti, Sebastiano</creatorcontrib><creatorcontrib>Zustovich, Fable</creatorcontrib><creatorcontrib>Sepe, Pierangela</creatorcontrib><creatorcontrib>Rossetti, Sabrina</creatorcontrib><creatorcontrib>Maruzzo, Marco</creatorcontrib><creatorcontrib>Cortesi, Enrico</creatorcontrib><creatorcontrib>Tortora, Giampaolo</creatorcontrib><creatorcontrib>Procopio, Giuseppe</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Targeted oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iacovelli, Roberto</au><au>Ciccarese, Chiara</au><au>Facchini, Gaetano</au><au>Milella, Michele</au><au>Urbano, Federica</au><au>Basso, Umberto</au><au>De Giorgi, Ugo</au><au>Sabbatini, Roberto</au><au>Santini, Daniele</au><au>Berardi, Rossana</au><au>Santoni, Matteo</au><au>Bracarda, Sergio</au><au>Massari, Francesco</au><au>Masini, Cristina</au><au>De Tursi, Michele</au><au>Ricotta, Riccardo</au><au>Buti, Sebastiano</au><au>Zustovich, Fable</au><au>Sepe, Pierangela</au><au>Rossetti, Sabrina</au><au>Maruzzo, Marco</au><au>Cortesi, Enrico</au><au>Tortora, Giampaolo</au><au>Procopio, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis</atitle><jtitle>Targeted oncology</jtitle><stitle>Targ Oncol</stitle><addtitle>Target Oncol</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>15</volume><issue>4</issue><spage>495</spage><epage>501</epage><pages>495-501</pages><issn>1776-2596</issn><eissn>1776-260X</eissn><abstract>Background
Angiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC). However, few clinical data are available regarding the efficacy of cabozantinib following immunotherapy.
Objective
To describe the outcome of cabozantinib in patients previously treated with immunotherapy.
Patients and methods
Patients with mRCC who received cabozantinib immediately after nivolumab were included. The primary endpoint was to assess the outcome in terms of efficacy and activity.
Results
Eighty-four mRCC patients met the criteria to be included in the final analysis. After a median follow-up of 9.4 months, median overall survival was 17.3 months. According to the IMDC criteria, the rates of patients alive at 12 months in the good, intermediate, and poor prognostic groups were 100%, 74%, and 33%, respectively (
p
< 0.001). The median progression-free survival (PFS) was 11.5 months (95% CI 8.3–14.7); no difference was found based on duration of previous first-line therapy or nivolumab PFS. The overall response rate was 52%, stable disease was found as the best response in 25.3% and progressive disease in 22.7% of patients. Among the 35 patients with progressive disease on nivolumab, 26 (74.3%) patients showed complete/partial response or stable disease with cabozantinib as best response after nivolumab. The major limitations of this study are the retrospective nature and the short follow-up.
Conclusions
Cabozantinib was shown to be effective and active in patients previously receiving immune checkpoint inhibitors. Therefore, cabozantinib can be considered a valid therapeutic option for previously treated mRCC patients, irrespective of the type and duration of prior therapies.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32671807</pmid><doi>10.1007/s11523-020-00732-y</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1776-2596 |
| ispartof | Targeted oncology, 2020-08, Vol.15 (4), p.495-501 |
| issn | 1776-2596 1776-260X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2424446591 |
| source | SpringerLink Journals |
| subjects | Biomedicine Immunotherapy Inhibitor drugs Kidney cancer Medicine Medicine & Public Health Metastasis Monoclonal antibodies Oncology Original Research Article Targeted cancer therapy |
| title | Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T03%3A46%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cabozantinib%20After%20a%20Previous%20Immune%20Checkpoint%20Inhibitor%20in%20Metastatic%20Renal%20Cell%20Carcinoma:%20A%20Retrospective%20Multi-Institutional%20Analysis&rft.jtitle=Targeted%20oncology&rft.au=Iacovelli,%20Roberto&rft.date=2020-08-01&rft.volume=15&rft.issue=4&rft.spage=495&rft.epage=501&rft.pages=495-501&rft.issn=1776-2596&rft.eissn=1776-260X&rft_id=info:doi/10.1007/s11523-020-00732-y&rft_dat=%3Cproquest_cross%3E2424446591%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2435028346&rft_id=info:pmid/32671807&rfr_iscdi=true |